Daphne Karydas
CIK: 0001816952
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Sep 15, 2026MLYS
Mineralys Therapeutics, Inc.
Exercise(M)Direct3K shares at avg. $12.02$36K - Sep 15, 2026MLYS
Mineralys Therapeutics, Inc.
Sale(S)Direct3K shares at avg. $28.58$86K - Jun 17, 2026MLYS
Mineralys Therapeutics, Inc.
Sale(S)Direct3K shares at avg. $25.00$75K - Jun 17, 2026MLYS
Mineralys Therapeutics, Inc.
Exercise(M)Direct3K shares at avg. $12.02$36K - May 27, 2026CMPS
COMPASS Pathways plc
Award(A)DirectShare Option (Right to Buy)
21.1K shares- - Mar 31, 2026MLYS
Mineralys Therapeutics, Inc.
Exercise(M)Direct3K shares at avg. $12.02$36K - Mar 31, 2026MLYS
Mineralys Therapeutics, Inc.
Sale(S)Direct3K shares at avg. $25.00$75K - Feb 19, 2026MLYS
Mineralys Therapeutics, Inc.
Award(A)Direct6.2K shares- - Nov 13, 2025MLYS
Mineralys Therapeutics, Inc.
Sale(S)Direct10.1K shares at avg. $45.81$463K - Nov 13, 2025MLYS
Mineralys Therapeutics, Inc.
Exercise(M)Direct15K shares at avg. $10.20$153K - Nov 13, 2025MLYS
Mineralys Therapeutics, Inc.
Sale(S)Direct4.9K shares at avg. $46.36$226K - Jun 12, 2025CMPS
COMPASS Pathways plc
Award(A)DirectShare Option (Right to Buy)
26K shares- - Feb 13, 2025MLYS
Mineralys Therapeutics, Inc.
Award(A)DirectStock Option
32.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 15, 2026 |  MLYS Mineralys Therapeutics, Inc. | Exercise(M) | 3,000 | $12.02 | $36,060 | Direct |
| Sep 15, 2026 | MLYS Mineralys Therapeutics, Inc. | Sale(S) | 3,000 | $28.58 | $85,740 | Direct |
| Jun 17, 2026 | MLYS Mineralys Therapeutics, Inc. | Sale(S) | 3,000 | $25.00 | $75,000 | Direct |
| Jun 17, 2026 | MLYS Mineralys Therapeutics, Inc. | Exercise(M) | 3,000 | $12.02 | $36,060 | Direct |
| May 27, 2026 |  CMPS COMPASS Pathways plc | Award(A) Share Option (Right to Buy) | 21,110 | - | - | Direct |
| Mar 31, 2026 | MLYS Mineralys Therapeutics, Inc. | Exercise(M) | 3,000 | $12.02 | $36,060 | Direct |
| Mar 31, 2026 | MLYS Mineralys Therapeutics, Inc. | Sale(S) | 3,000 | $25.00 | $75,000 | Direct |
| Feb 19, 2026 | MLYS Mineralys Therapeutics, Inc. | Award(A) | 6,200 | - | $0 | Direct |
| Nov 13, 2025 | MLYS Mineralys Therapeutics, Inc. | Sale(S) | 10,115 | $45.81 | $463,351 | Direct |
| Nov 13, 2025 | MLYS Mineralys Therapeutics, Inc. | Exercise(M) | 15,000 | $10.20 | $153,000 | Direct |
| Nov 13, 2025 | MLYS Mineralys Therapeutics, Inc. | Sale(S) | 4,885 | $46.36 | $226,446 | Direct |
| Jun 12, 2025 | CMPS COMPASS Pathways plc | Award(A) Share Option (Right to Buy) | 26,000 | - | - | Direct |
| Feb 13, 2025 | MLYS Mineralys Therapeutics, Inc. | Award(A) Stock Option | 32,900 | - | - | Direct |
1-13 of 13 transactions
About Karydas Daphne
Karydas Daphne (SEC CIK 0001816952) files insider reports with the SEC as Director of Mineralys Therapeutics, Inc. (MLYS) and Director of COMPASS Pathways plc (CMPS).
Signal8 holds 8 ownership filings by Karydas Daphne, all Form 4s, filed between Feb 24, 2025 and Sep 17, 2026. Those filings report 13 transactions, from Feb 13, 2025 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Karydas Daphne's filings is in RADNOR, PA.
Recent filings by Karydas Daphne
- Sep 15, 2026: Option exercise of MLYS shares (Form 4, code M).
- Sep 15, 2026: Open-market sale of MLYS shares (Form 4, code S).
- Jun 17, 2026: Open-market sale of MLYS shares (Form 4, code S).
- Jun 17, 2026: Option exercise of MLYS shares (Form 4, code M).
- May 27, 2026: Grant or award of CMPS derivative securities (Form 4, code A).
Other insiders filing for Mineralys Therapeutics, Inc. (MLYS)
- Peterson Kristine, Director
- COATS LONNEL, Director
- Congleton Jon, Chief Executive Officer
- Slingsby Brian Taylor, Director
- Warren Eric, Chief Commercial Officer
- Ferguson James J. III, Chief Medical Officer